Genmab — December 2025
-
Hvis man trænger til lidt underholdning, så er der jo altid Saxos vilde forudsigelser.https://www.home.saxo/da-dk/insights/news-and-research/thought-leadership/outrageous-predictions
-
FDA Proactively Awards National Priority Voucher Based on Strong Phase 3 Study Results
For Immediate Release:
December 15, 2025The U.S. Food and Drug Administration today awarded a national priority voucher to teclistamab in combination with daratumumab for relapsed/refractory multiple myeloma. https://www.fda.gov/news-events/press-announcements/fda-proactively-awards-national-priority-voucher-based-strong-phase-3-study-results
-
Cami still manages an article in Blood... Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study https://ashpublications.org/bloodadvances/article/9/23/6205/546723/Camidanlumab-tesirine-for-relapsed-or-refractory
-
small new trial - Phase I/II Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma https://clinicaltrials.gov/study/NCT07283679
-
Genmab får løftet kursmålet til 2900 kr. hos Kempen https://proinvestor.com/investornyt/1394515/genmab-far-loftet-kursmalet-til-2900-kr-hos-kempen
-
Genmabs partner får udvidet godkendelse til lungekræftmiddel fra FDA https://proinvestor.com/investornyt/1394808/genmabs-partner-far-udvidet-godkendelse-til-lungekraeftmiddel-fra-fda
-
subcutaneous - U.S. FDA Approval of RYBREVANT FASPRO
(amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when combined with LAZCLUZE
(lazertinib) https://www.jnj.com/media-center/press-releases/u-s-fda-approval-of-rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-enables-the-simplest-shortest-administration-time-for-a-first-line-combination-regimen-when-combined-with-lazcluze-lazertinib -
RAINFOL-05 ! New trial - Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer https://clinicaltrials.gov/study/NCT07288177
-
Genmab’s Rina-S: New Study Targets Lung Cancer with Innovative Treatment https://www.tipranks.com/news/company-announcements/genmabs-rina-s-new-study-targets-lung-cancer-with-innovative-treatment
-
Kort video: De amerikanske aktier, som er lokomotivet for det globale aktiemarked, har været negative de sidste fire-fem dage. Helge Larsen fortæller om årsagerne og kigger derudover selskabsspecifikt på Anavex, som skal til reeksamen, Bavarian Nordics fremtid, opdatering på Novo Nordisk og Genmab, og til sidst Zealand Pharma, hvor der torsdag er Q&A med CEO Adam Steensberg https://proinvestor.com/boards/130406
-
yesterday : Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma https://ir.pyxisoncology.com/news-releases/news-release-details/pyxis-oncology-announces-positive-preliminary-phase-1-data --> PYXS fell 48% on this
-
How Adding epcoritamab to standard second-line therapy improves follicular lymphoma outcomes https://healthmedicinet.com/hmn-2025-how-adding-epcoritamab-standard-line-therapy/ "We will not know for a long time if [this regimen] is curative, but it’s certainly the beginning of a bright era for chemo-free therapy for follicular lymphoma.”
enig lahn1...
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind